ACON

Aclarion, Inc. · NASDAQ

Sector Technology Services
Industry Packaged Software
Website aclarion.com
Employees(FY) -
ISIN US6551872012

Performance

-3.08%

-0.9%

-27.44%

-45.64%

-94.49%

YTD

-95.86%

Profile

Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. The company develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in Broomfield, Colorado.

Advanced Technical Analysis

Technical Analysis of ACON 2024-11-20

The stock indicators reflect a bearish sentiment, with the Moving Average Score at 26, Oscillators Score at 43, and a Technical Score of 35, indicating overall weakness in price momentum and suggesting caution for potential investors. The low scores across all categories highlight a lack of bullish signals, reinforcing a negative outlook for the...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of ACON

Stock Rank

Recent News & Updates

2024-11-14 04:00
Aclarion to Present at the Virtual Investor Summit Microcap Event on November 21st(Accesswire)
2024-10-09 19:00
Aclarion to Participate in the 2024 Maxim Healthcare Virtual Summit(Globenewswire)
2024-09-26 18:57
Aclarion's Nociscan AI Plays Key Role in Advanced Understanding of Modic Changes(Globenewswire)
2024-09-12 20:30
PRISM MarketView Showcases Aclarion: Disrupting Chronic Pain Treatment with Nociscan AI Technology(Globenewswire)
2024-09-11 18:57
Aclarion Provides Corporate Update on Nociscan AI Technology Milestones(Globenewswire)
2024-09-11 18:00
Transforming Oncology: Stocks to Watch in the Oncology Sector(Newsdirect)
2024-09-11 01:00
Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing(Accesswire)
2024-09-10 18:00
Aclarion, Inc.'s (NASDAQ: ACON) Emerging Role in the Back Pain Management Sector(Newsdirect)
2024-09-09 18:57
Aclarion Announces Completion of First Nociscan Exams in LIFEHAB Trial(Globenewswire)
2024-09-05 23:27
Aclarion Added to PRISM Emerging Medical Devices Index(Globenewswire)
2024-09-04 18:57
Aclarion Launches Surgeon Partnership to Apply Nociscan's AI Technology to Personal Injury and Workers Compensation Market(Globenewswire)
2024-08-28 18:57
Aclarion Launches Second Clinical Utility and Economic (CLUE) Trial Site With First Surgeon in New Jersey(Globenewswire)
2024-08-20 19:57
Aclarion Launches the Clinical Utility and Economic (CLUE) Trial to Quantify How Often Nociscan's AI Generated Biomarker Data Changes Surgical Treatment Plans(Globenewswire)
2024-08-14 21:48
Aclarion to Present at August 20th Virtual Investor Summit Microcap Event(Globenewswire)
2024-08-13 20:08
Aclarion Announces First Commercial Agreement in Michigan(Globenewswire)
2024-08-12 21:07
Aclarion Hits Another Key Milestone by Adding Vitality - Third Major Payer to Cover Nociscan in Greater UK(Globenewswire)
2024-07-08 19:00
Aclarion Achieves Milestone With Key Second Payer Coverage of Nociscan by Aviva Throughout Greater London, UK(Globenewswire)
2024-06-25 20:30
Aclarion Announces Initial Payer Coverage of Nociscan by AXA Throughout Greater London, UK(Globenewswire)
2024-06-24 20:30
Aclarion Expands Commercial Engagement With The London Clinic to Grow Access to Nociscan Throughout Greater London(Globenewswire)
2024-06-19 20:00
Aclarion Receives Notice of Allowance for US Patent to Support Further Optimization of Accuracy and Reliability in the Nociscan Solution(Yahoo Finance)
2024-06-17 19:00
Aclarion Announces Updated Product Release That Enhances User-Experience, Scalability, and Security for Nociscan Solution(Yahoo Finance)
2024-05-15 10:55
ACON Stock Earnings: Aclarion Reported Results for Q1 2024(Investorplace)
2024-04-28 21:00
Keynotes, Educational Panels and 96 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NV(Accesswire)
2024-04-24 21:14
Aclarion's Nociscan Solution to Play Key Role in Groundbreaking LIFEHAB Trial Evaluating the Diagnosis and Treatment of Chronic Low Back Pain(Globenewswire)
2024-04-22 20:00
Aclarion to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024(Yahoo Finance)
2024-03-03 19:00
Aclarion Announces Publication of Compelling Peer-Reviewed Data in International Journal of Spine Surgery Supporting Nociscan as a Gold Standard for Noninvasive Identification of Painful Lumbar Discs(Globenewswire)
2024-02-27 02:22
Aclarion Announces Closing of $3.0 Million Public Offering(Globenewswire)
2024-02-25 20:15
Aclarion Announces Pricing of $3.0 Million Public Offering(Globenewswire)
2024-02-25 19:42
Why Is Aclarion (ACON) Stock Down 19% Today?(Investorplace)
2024-02-04 19:00
Aclarion Announces Successful Financings; Plans to Launch CLARITY Trial and Provides Update on Next Steps of Alphatec Strategic Partnership(Globenewswire)

Page 1 of 3

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.